CervoMed, Inc.

US initial public offerings by biopharmaceutical companies appear to be on the rise in 2024 with nine during the first quarter, including Boundless Bio Inc. ’s $100m IPO on 27 March, outpacing 2023 w

Private biotech EIP Pharma, Inc. and publicly traded Diffusion Pharmaceuticals, Inc. are entering an all-stock merger to create a new firm focused on CNS therapeutics with an eye to bringing the f

Roche Holding AG has abandoned its Phase III trial studying the investigational drug tominersen in Huntington's disease, ending hopes the antisense oligonucleotide could offer a game-changing therapy

Of the record number of 19 compounds Roche Holding AG has in Phase III trials or filed for approval, the two that are targeting Alzheimer's and Huntington's disease – gantenerumab and tominersen, re